logo
logo

Cf Foundation Invests Up To $8.4M In Splisense For The Development Of Potential Rare Mutation Therapy

May 13, 2021•about 4 years ago

Amount Raised

$8.4 Million

Manchester

Description

Today, the Cystic Fibrosis Foundation announced that it will invest up to $8.4 million in SpliSense’s Series B funding round to develop an antisense oligonucleotide (ASO) therapy for people with cystic fibrosis who have splicing mutations and potentially other rare mutations. The investment is part of the Foundation’s Path to a Cure, a research agenda to accelerate treatments for the underlying cause of cystic fibrosis for every person with CF.

Company Information

Company

Development

Location

Manchester, New Hampshire, United States

About

Our teams are aligned on the vision to deliver a world-class sustainable commercial space and new public realm in the city and will be working on the final stages of design in the coming months.”The development has the full support of Manchester City Council.Sir Richard Leese, Leader of Manchester City Council, said: “Navigating the complexities of this development within the constraints of the site has undoubtedly been challenging, but we know the outcome is going to be truly transformational for this part of the city centre - with world class place making key to its success.